DPTX3186 in Wnt Pathway Activated Solid Tumors

Summary

This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy

Timeline

Start

2026-01

Primary completion

2028-05-31

Completion

2028-06-30

Drugs

Indications